<?xml version="1.0" ?>
<!DOCTYPE pmc-articleset PUBLIC "-//NLM//DTD ARTICLE SET 2.0//EN" "https://dtd.nlm.nih.gov/ncbi/pmc/articleset/nlm-articleset-2.0.dtd">

<pmc-articleset><article article-type="research-article" xmlns:mml="http://www.w3.org/1998/Math/MathML" xmlns:xlink="http://www.w3.org/1999/xlink">
<!--The publisher of this article does not allow downloading of the full text in XML form.-->
<?properties manuscript?>
<front>
<journal-meta>
<journal-id journal-id-type="nlm-journal-id">9106748</journal-id>
<journal-id journal-id-type="pubmed-jr-id">8519</journal-id>
<journal-id journal-id-type="nlm-ta">Psychiatr Genet</journal-id>
<journal-id journal-id-type="iso-abbrev">Psychiatr. Genet.</journal-id>
<journal-title-group>
<journal-title>Psychiatric genetics</journal-title>
</journal-title-group>
<issn pub-type="ppub">0955-8829</issn>
<issn pub-type="epub">1473-5873</issn>
</journal-meta>
<article-meta>
<article-id pub-id-type="pmid">26555645</article-id>
<article-id pub-id-type="pmc">4756433</article-id>
<article-id pub-id-type="doi">10.1097/YPG.0000000000000110</article-id>
<article-id pub-id-type="manuscript">EMS65242</article-id>
<article-categories>
<subj-group subj-group-type="heading">
<subject>Article</subject>
</subj-group>
</article-categories>
<title-group>
<article-title>Mutation screening of <italic>SCN2A</italic> in schizophrenia and identification of a novel loss-of-function mutation</article-title>
</title-group>
<contrib-group>
<contrib contrib-type="author">
<name>
<surname>Carroll</surname>
<given-names>Liam S</given-names>
</name>
</contrib>
<contrib contrib-type="author">
<name>
<surname>Woolf</surname>
<given-names>Rebecca</given-names>
</name>
</contrib>
<contrib contrib-type="author">
<name>
<surname>Ibrahim</surname>
<given-names>Yousef</given-names>
</name>
</contrib>
<contrib contrib-type="author">
<name>
<surname>Williams</surname>
<given-names>Hywel J</given-names>
</name>
</contrib>
<contrib contrib-type="author">
<name>
<surname>Dwyer</surname>
<given-names>Sarah</given-names>
</name>
</contrib>
<contrib contrib-type="author">
<name>
<surname>Walters</surname>
<given-names>James</given-names>
</name>
</contrib>
<contrib contrib-type="author">
<name>
<surname>Kirov</surname>
<given-names>George</given-names>
</name>
</contrib>
<contrib contrib-type="author">
<name>
<surname>Oâ€™Donovan</surname>
<given-names>Michael C</given-names>
</name>
</contrib>
<contrib contrib-type="author">
<name>
<surname>Owen</surname>
<given-names>Michael J</given-names>
</name>
</contrib>
<aff id="A1">MRC Centre for Neuropsychiatric Genetics and Genomics, Institute of Psychological Medicine and Clinical Neurosciences, Cardiff University, Cardiff, UK</aff>
</contrib-group>
<author-notes>
<corresp id="CR1">Corresponding author: Liam Carroll, MRC Centre for Neuropsychiatric Genetics and Genomics, Institute of Psychological Medicine and Clinical Neurosciences, Cardiff University, Cardiff, UK. <email>liamcarroll@nhs.net</email></corresp>
</author-notes>
<pub-date pub-type="nihms-submitted">
<day>9</day>
<month>10</month>
<year>2015</year>
</pub-date>
<pub-date pub-type="ppub">
<month>4</month>
<year>2016</year>
</pub-date>
<pub-date pub-type="pmc-release">
<day>01</day>
<month>10</month>
<year>2016</year>
</pub-date>
<volume>26</volume>
<issue>2</issue>
<fpage>60</fpage>
<lpage>65</lpage>
<!--elocation-id from pubmed: 10.1097/YPG.0000000000000110-->
<abstract>
<sec id="S1">
<title>Objectives</title>
<p id="P1">There is a growing body of evidence suggesting a shared genetic susceptibility between many neuropsychiatric disorders, including schizophrenia, autism, intellectual disability and epilepsy. The sodium channel, voltage-gated type II alpha subunit gene <italic>SCN2A</italic> has been shown to exhibit loss-of-function mutations in individuals with seizure disorders, intellectual disability, autism and schizophrenia. The role of loss-of-function mutations in schizophrenia is still uncertain with only one such mutation identified to date.</p>
</sec>
<sec id="S2">
<title>Methods</title>
<p id="P2">To seek additional evidence for a role for loss-of-function mutations at <italic>SCN2A</italic> in schizophrenia we performed mutation screening of the entire coding sequence in 980 schizophrenia cases. Given an absence of LoF mutations in a public exome cohort (ESP6500, N=6503) we did not additionally sequence controls.</p>
</sec>
<sec id="S3">
<title>Results</title>
<p id="P3">We identify a novel, nonsense (i.e. stop-codon) mutation in one case (E169X) that is absent in 4300 European American and 2203 African-American individuals from the NHLBI Exome Sequencing Project. This is the second loss-of-function allele identified in a schizophrenia case to date. We also show a novel, missense variant, V1282F, that occurs in 2-cases and is absent in the control dataset.</p>
</sec>
<sec id="S4">
<title>Conclusion</title>
<p id="P4">We argue that very rare, loss-of-function mutations at <italic>SCN2A</italic> act in a moderately penetrant manner to increase the risk of developing several neuropsychiatric disorders including seizure disorders, intellectual disability, autism and schizophrenia.</p>
</sec>
</abstract>
<kwd-group>
<kwd>Schizophrenia</kwd>
<kwd>gene</kwd>
<kwd>mutation</kwd>
<kwd>nonsense</kwd>
<kwd>missense</kwd>
<kwd>loss-of-function</kwd>
</kwd-group>
</article-meta>
</front>
</article>
</pmc-articleset>